News & Events

News


Tuesday November 12, 2019

Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia

- Approximately 90% of Patients Treated with INGREZZA in the Open-Label KINECT 4 Phase III Study Achieved a 50% or Greater Improvement in Their Tardive Dyskinesia Symptoms - INGREZZA Continues to Be Well Tolerated Through One Year of Treatment SAN DIEGO , Nov.


Tuesday November 05, 2019

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO , Nov. 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Matt Abernethy , Chief Financial Officer, will present at the Credit Suisse 28 th Annual Healthcare


Monday November 04, 2019

Neurocrine Biosciences Reports Third Quarter 2019 Financial Results

INGREZZA® (valbenazine) Third Quarter Net Product Sales of $198.1 Million with Approximately 34,800 TRx Initiated KINECT-HD Phase III Study of Valbenazine to Treat Chorea in Patients with Huntington's Disease SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc.


Monday October 14, 2019

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results

Conference Call and Webcast Scheduled for Monday, November 4 SAN DIEGO , Oct. 14, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, November 4, 2019 .


Friday October 04, 2019

Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

- Pooled Data Analyses from Long-Term Studies Show that the 40 mg Once-Daily Dose of INGREZZA is Effective in Reducing Abnormal Movements in Adults with Tardive Dyskinesia   - Data Analysis Indicates that INGREZZA Improved Tardive Dyskinesia Movements as Early as Two Weeks in 50% of Patients   -

Events